Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Plus High-Dose Chemotherapy With Autologous Stem Cell Support for Poor-Prognosis NHL
NCT00141700Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Mar 2003
- Primary completion
- Mar 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in non-Hodgkin lymphoma (NHL), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Progression-Free Survival. Started Mar 2003; status: terminated.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00141700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141700.